Table 11.6f
Immunosuppression Use for Maintenance by Regimen
One Year Following Transplantation, 1995 to 2004
Recipients with Heart Transplants

	Transplant Year									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	2,363	2,343	2,293	2,348	2,188	2,199	2,202	2,155	2,057	2,016
Functioning Graft at 1 Year PostTx	1,907	1,932	1,876	1,939	1,780	1,820	1,851	1,820	1,754	1,718
With Maintenance Use Recorded at 1 Year PostTx	145	168	221	1,083	1,724	1,756	1,830	1,785	1,717	1,709
--- + MMF/MPA	0.7%	0.6%	0.9%	0.2%	0.1%	0.2%	0.1%	0.2%	0.4%	0.2%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
--- + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.2%	0.2%
--- + MMF/MPA + Steroids	0.0%	0.0%	0.5%	0.6%	0.5%	0.8%	0.5%	0.6%	0.3%	0.6%
--- + OtherAntimet	1.4%	0.0%	0.0%	0.2%	0.2%	0.2%	0.1%	0.0%	0.1%	0.0%
--- + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%
--- + OtherAntimet + Steroids	0.0%	0.6%	0.0%	0.1%	0.1%	0.1%	0.2%	0.1%	0.1%	0.0%
--- + Siro/Evero	0.0%	0.0%	0.5%	0.0%	0.0%	0.0%	0.1%	0.0%	0.2%	0.0%
--- + Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	0.4%	0.3%	0.2%	0.1%
--- + Steroids	4.1%	3.0%	4.5%	5.4%	2.0%	2.2%	3.4%	0.4%	0.2%	0.4%
CyA	3.4%	0.6%	0.9%	1.0%	0.9%	1.3%	0.8%	0.8%	0.8%	0.3%
CyA + MMF/MPA	0.0%	2.4%	5.9%	7.6%	8.5%	9.7%	9.0%	8.6%	8.5%	8.5%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%
CyA + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.2%	0.5%	0.1%
CyA + MMF/MPA + Steroids	2.1%	21.4%	26.7%	36.4%	35.1%	40.9%	33.5%	27.6%	24.9%	23.5%
CyA + OtherAntimet	6.9%	7.7%	3.2%	3.6%	3.3%	2.3%	1.6%	2.4%	1.2%	1.4%
CyA + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	0.1%
CyA + OtherAntimet + Steroids	35.9%	32.1%	23.1%	15.1%	11.3%	6.6%	4.6%	3.2%	2.0%	2.7%
CyA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.2%	0.8%	0.8%	0.5%
CyA + Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.2%	1.2%	1.3%	0.8%	1.2%	2.5%	1.1%
CyA + Steroids	4.1%	4.8%	4.5%	2.6%	4.9%	3.6%	1.9%	1.9%	1.9%	0.9%
Tac	0.0%	1.8%	2.3%	1.2%	1.3%	1.1%	0.7%	1.6%	1.3%	1.2%
Tac + MMF/MPA	0.0%	0.6%	0.5%	2.2%	2.8%	3.4%	6.9%	6.3%	10.4%	10.8%
Tac + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%	0.3%	0.2%	0.3%
Tac + MMF/MPA + Steroids	0.0%	2.4%	8.6%	13.9%	14.6%	17.0%	21.2%	25.0%	25.6%	32.1%
Tac + OtherAntimet	0.0%	1.2%	0.0%	0.5%	0.9%	0.9%	0.9%	1.1%	1.0%	1.3%
Tac + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%	0.0%	0.1%
Tac + OtherAntimet + Steroids	6.2%	3.6%	6.3%	4.2%	3.4%	1.9%	2.6%	1.9%	2.1%	1.5%
Tac + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.2%	1.3%	1.5%	0.9%
Tac + Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.3%	0.5%	1.0%	2.9%	4.5%	4.4%	2.1%
Tac + Steroids	2.8%	2.4%	3.2%	2.4%	2.3%	2.3%	4.3%	3.5%	3.0%	2.6%
Other Regimen	32.4%	14.9%	8.6%	2.6%	5.9%	2.7%	3.1%	6.0%	5.5%	6.3%

Source: OPTN/SRTR Data as of May 1, 2006.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at one year following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.